Targeting thioredoxin reductase for anti-tuberculosis drug discovery: the inhibitor OSSL_632214
Authors:
Open Access
- 6 July 2026
- journal article
- research article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 110 (1)
Abstract
The persistent prevalence of multidrug-resistant tuberculosis (TB) and extensively drug-resistant TB has progressively undermined the efficacy of TB infectKeywords
This publication has 19 references indexed in Scilit:
- Design, synthesis and antimycobacterial activity of novel benzothiazinones with improved water solubilityEuropean Journal of Medicinal Chemistry, 2024
- The role of thioredoxin system in the maintenance of redox homeostasis in Mycobacterium tuberculosisProceedings of the Indian National Science Academy, 2024
- An Update on the Clinical Pipelines of New Antibacterial Drugs Developed in ChinaEngineering, 2024
- High-throughput fluorescent screening of thioredoxin reductase inhibitors to inhibit Mycobacterium tuberculosisChinese Chemical Letters, 2023
- Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trialThe Lancet Respiratory Medicine, 2021
- AC2P20 selectively kills Mycobacterium tuberculosis at acidic pH by depleting free thiolsRSC Advances, 2021
- The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host's immune systemBiochemical Journal, 2020
- Synthesis of N-substituted imidazo[4,5-e]benzo[1,2-c;3,4-c’]difuroxansRussian Chemical Bulletin, 2017
- Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasisProceedings of the National Academy of Sciences, 2015
- The thioredoxin antioxidant systemFree Radical Biology and Medicine, 2014